Note: Should you have landed here as a result of a search engine (or other) link, be advised that these files contain material that is copyrighted by the American Medical Association. You are forbidden to download the files unless you read, agree to, and abide by the provisions of the copyright statement. Read the copyright statement now and you will be linked back to here.
Link to ArticleContractor Name
CareFirst of Maryland Inc., Medicare Part A
Contractor Number
00190
Contractor Type
Fiscal Intermediary
LCD Database ID Number
L747
LCD Title
Cryosurgery in the Treatment of Liver Tumors
Contractor's Determination Number
00-05-R2
AMA/CPT and ADA/CDT Copyright Statement
CPT codes, descriptions, and other data only are copyright 1999 American Medical Association (or such publication of CPT). All rights reserved. Applicable FARS/DFARS clauses apply. CDT-4 codes and descriptions are ©2004 American Dental Association. All rights reserved.
CMS National Coverage Policy
Primary Geographic Jurisdiction
Maryland
Washington, DC
Secondary Geographic Jurisdiction
Alabama, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois, Iowa, Kansas, Kentucky, Louisiana, Maine, Massachusetts, Michigan, Missouri, Nebraska, Nevada, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Wisconsin, Washington state, and Wyoming
Oversight Region
Region III
CMS Consortium
Northeast
Original Determination Effective Date
06/26/2000
Revision Effective Date
Indications and Limitations of Coverage and/or Medical Necessity
Description
Cryosurgery is a means for surgical destruction of diseased tissue. It has been used for many years in many medical fields including dermatology, neurosurgery, proctology, gynecology, and otolaryngology. In the last 10-15 years, much work has been done in applying this modality to the treatment of liver tumors, both primary and metastatic The biggest breakthrough in the field of cryosurgery for liver tumors has been the application of intraoperative ultrasound both to detect small lesions and to monitor the cryosurgical destruction process in order to assure complete ablation of the desired lesion, with a margin of normal tissue. In the treatment of liver tumors, cryosurgical destruction is often used in addition to surgical resection.
Indications and Limitations
Cryosurgery in the treatment of certain selected primary and secondary liver tumors is considered safe and effective in the following clinical scenarios:
Note: Metastases to the liver from primary carcinomas of the breast, lung, stomach, pancreas, adenocarcinoma of unknown origin, and other such primaries that tend to be disseminated widely at the same time that liver metastases are present, are not appropriate for treatment by cryosurgical ablation.
Coverage Topic
Bill Type Codes
11X, 13X, 21X, 83X
Revenue Codes
360, 402
CPT/HCPCS Codes
The AMA and CMS require the use of short descriptors for policies published on the Web. Refer to the CPT book for the long description of the following codes:
|
47371 |
|
Laparo ablate liver cryosurg |
|
47381 |
|
Open ablate liver tumor cryo |
|
76986 |
|
Ultrasound guide intraoper |
|
76490 |
|
Ultrasound guidance, tissue ablation |
Does the “CPT 30%
Coding Rule” Apply?
N/A
ICD-9 Codes that Support Medical Necessity
When procedure code 47381 with or without 76490 or 76986 are used to report "Cryosurgery in the Treatment of Liver Tumors" as described within this policy, the following diagnosis code(s) will be considered by Medicare to support medical necessity:
|
152.0 |
|
Malignant neoplasm of small intestine; duodenum |
|
152.1 |
|
|
|
152.2 |
|
|
|
152.8 |
|
Other specified sites of small intestine |
|
152.9 |
|
Small intestine, unspecified |
|
153.0 |
|
Malignant neoplasm of colon; hepatic flexure |
|
153.1 |
|
|
|
153.2 |
|
|
|
153.3 |
|
|
|
153.4 |
|
|
|
153.5 |
|
|
|
153.6 |
|
|
|
153.7 |
|
|
|
153.8 |
|
|
|
153.9 |
|
|
|
154.0 |
|
Malignant neoplasm; rectosigmoid junction |
|
154.1 |
|
|
|
154.2 |
|
|
|
154.3 |
|
|
|
154.8 |
|
Other |
|
155.0 |
|
Malignant neoplasm of liver, primary |
|
183.00 |
|
Malignant neoplasm of ovary |
|
197.7 |
|
Secondary malignant neoplasm of liver |
Diagnoses that Support Medical Necessity
N/A
ICD-9 Codes that DO NOT Support Medical Necessity
Any diagnosis codes not listed in the "ICD-9 Codes that Support Medical Necessity" section of this policy
Diagnoses that DO NOT Support Medical Necessity
Conditions not listed in the "ICD-9 Codes that Support Medical Necessity" section of this policy.
Documentation Requirements
Utilization Guidelines
N/A
Sources of Information and Basis for Decision
Advisory Committee Notes
This policy does not reflect the sole opinion of the contractor or Contractor Medical Director. Although the final decision rests with the contractor, this policy was developed in cooperation with advisory groups, which includes representatives from the appropriate specialty (ies).
Advisory Committee Meeting Date: N/A
Start Date of Comment Period
End Date of Comment Period
Start Date of Notice Period
Revision History
|
Number |
|
Date |
|
Change |
|
R-2 |
|
|
|
Modified revenue
codes, to include only 360 and 402 to make more |
|
|
|
|
|
specific to the
policy. Converted from LMRP to LCD. |
|
00-05-R1 |
|
|
|
Expanded coverage with addition of |
|
|
|
|
|
HCPCS 47381 replaced 49200. CPT descriptors changed to short |
|
|
|
|
|
descriptor, ICD-9 codes unranged. |
THIS BULLETIN SHOULD BE SHARED WITH ALL
HEALTH CARE PRACTITIONERS AND MANAGERIAL MEMBERS OF THE PROVIDER/SUPPLIER
STAFF. BULLETINS ISSUED AFTER
Italicized and or quoted material is excerpted from the American Medical Association Current Procedural Terminology CPT codes, descriptions and other data only are copyrighted 1999 American Medical Association (or such other publication of CPT). All rights reserved. Applicable FARS/DFARS apply.